Actively Recruiting
SOURCE Lung Phase II Study of Image-Guided Stereotactic Ablative Radiation Therapy for High-Risk Central Non-Small Cell Lung Tumors and Single Lung Metastases
Led by Cancer Trials Ireland · Updated on 2025-05-02
68
Participants Needed
2
Research Sites
208 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety of a radiation therapy method called image-guided stereotactic ablative radiation therapy IG-SABR for patients with high-risk centrally located non-small cell lung cancer NSCLC tumors or a single pulmonary oligometastatic lesion. This phase II, non-randomized study focuses on patients whose disease cannot be treated with surgery and aims to assess side effects by monitoring the number and severity of treatment-related toxicities. Patients must meet specific criteria related to tumor and normal tissue radiation doses to be eligible. Treatment involves delivering radiation in 8 sessions fractions, each with a dose of 7.5 Gy, using IG-SABR techniques that carefully target the tumor while respecting dose limits for surrounding normal tissues. The planning allows a minimum dose coverage between 75% and 95% of the planning target volume PTV and 75% to 99% of the gross tumor volume GTV. Respiratory monitoring will be used during treatment, which employs photon beams of 6-10 MV energy. Optional translational sub-studies involve biomarker discovery and protein analysis and are available only at participating centers. Participants will be assessed weekly during treatment and at multiple time points after treatment, including 2, 4, 8 weeks, and then at 3, 6, 9, 12, 18, 24 months, followed by annual visits up to 5 years. These evaluations include toxicity monitoring and survival assessments. The main outcome measured is the rate of severe treatment-related toxicity within one year after treatment. The study aims to include 60 evaluable patients and will stop enrolling if excessive severe side effects occur. The study period includes up to 5 years of follow-up for long-term safety and effectiveness outcomes.
CONDITIONS
Brief Title
'SOURCE - LUNG' Stereotactic Ablative Radiation Therapy Of UltRaCEntral LUNG Tumours (SOURCE Lung)
Research Team
C
Cancer Trials Ireland
P
Prof. John Armstrong
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here